Northern RNA

What Northern RNA does

Northern RNA Inc. is a privately held Canadian contract development and manufacturing organization (CDMO) founded in 2020 in Calgary, Alberta, specializing in GMP-grade nucleic acid products for the mRNA and DNA therapeutic, vaccine, and gene editing markets. The company's core technology stack spans plasmid DNA production, mRNA synthesis, proprietary cap analog chemistry (Co Cap™ A), in-house lipid manufacturing, single-use GMP lipid nanoparticle (LNP) formulation, microbial cell banking, and analytical and stability testing under ISO-classified cleanrooms (multiple cGMP Grade C plus one Grade B aseptic filling room). Production scales reach gram-scale for lipids and cap analogs and 100 mL to 10 L for the LNP platform, enabling clinical-to-commercial supply with lot traceability and full QA documentation. Differentiation is anchored in proprietary Co Cap™ A — a co-transcriptional cap analog with enhanced translational efficiency — proprietary purification methods achieving >99% lipid purity, and the ability to handle complex plasmid constructs with tandem repeats or GC-rich regions.

The business model combines project-based contract manufacturing services (B2B, quote-based, multi-year for GMP), off-the-shelf catalog product sales (GMP Grade Linear Plasmid DNA, GMP Grade mRNA, Co Cap™ A in research and GMP grades), and lipid/cap analog raw material sales. Northern RNA targets biotech and pharmaceutical companies (primary), RNA therapeutics developers (siRNA, sgRNA, ASO, PMO), and animal health firms, with customers in North America and select international markets. GTM is sales-led enterprise field sales supported by a contact form, LinkedIn presence, and industry conference activity (e.g., TIDES USA). The company has built a partnership ecosystem with Genvax Technologies (animal health contract manufacturing), Galenvs Sciences (oligonucleotide capabilities), SyVento BioTech (mRNA co-development), and Kaster Technologies (digital bioprocess tools). The leadership bench includes CEO Dr. Jared Davis (former Alexion, Arcturus, Providence; appointed June 2026) and a board featuring Dr. John Ballantyne, co-founder of Aldevron (acquired by Danaher for $9.6B).

Name

Northern RNA

Legal name

Northern RNA Inc.

Website

https://northernrna.com/

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Northern RNA is a Calgary-based, privately held CDMO founded in 2020 that provides GMP-grade plasmid DNA, mRNA, Co Cap™ A cap analogs, lipid manufacturing, and LNP formulation services to biotech, pharmaceutical, RNA therapeutics, and animal health companies globally.

Ownership category

akta.pro rank

Product category

Biopharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

akta.pro secondary industry

Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ)

Keywords

• MRNA contract manufacturing
• Nucleic acid CDMO
• Plasmid DNA production
• LNP formulation services
• GMP biomanufacturing

Headquarters

HQ city

Calgary

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: CDMO contract manufacturing services for nucleic acid products including plasmid DNA, mRNA, and LNP formulation. Services span from research grade through GMP clinical production. Revenue generated through project-based contracts with biotech and pharma companies.
2. Catalog Products: Off-the-shelf and custom-designed products including GMP Grade Linear Plasmid DNA, GMP Grade mRNA, and Co Cap™ A cap analogs sold directly to customers.
3. Lipid Manufacturing: Custom and generic lipid synthesis for LNP formulations sold as raw materials to biotech and pharmaceutical clients.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Northern RNA is a contract development and manufacturing organization (CDMO) that produces GMP-grade nucleic acid products including plasmid DNA, mRNA, cap analogs, and lipid nanoparticles for vaccine and therapeutic developers. The company offers end-to-end services spanning construct design, R&D development, microbial cell banking, chemical manufacturing, LNP formulation, fill/finish, analytical and stability testing, and cold chain storage, complemented by off-the-shelf and custom catalog products.

Product overview

Northern RNA is an end-to-end nucleic acid CDMO offering a portfolio of core products and manufacturing services. Its core products are GMP Grade Linear Plasmid DNA, GMP Grade mRNA, and Co Cap™ A cap analog, which together form the foundational building blocks for mRNA vaccine and therapeutic development. These are complemented by a catalog of reporter and popular constructs (EGFP, mCherry, tdTomato, Firefly Luciferase, Cas9, hEPO, Covid Spike Protein) available as plasmid or mRNA. The services suite spans the full development-to-commercial continuum: biomanufacturing, plasmid DNA production (research, GLP, and GMP grades), mRNA production (RUO and GMP), microbial cell banking, chemical manufacturing (cap analogs and lipids at gram to kilogram scale), LNP formulation, analytical and stability testing, storage services (chilled, frozen, cryogenic), and R&D development services including construct design, sequence optimization, and formulation development.

Differentiator

Problem solved

Functional benefit

Brands

• Co Cap™A: Proprietary mRNA co-transcriptional cap analog that enhances translational efficiency and protects against 5'–3' exonuclease degradation. Available in research and GMP grades.

Products and services

• GMP Grade Linear Plasmid DNA High-quality linear plasmid DNA produced under GMP conditions, used as a starting material for mRNA vaccine and therapeutic manufacturing.
• GMP Grade mRNA GMP-grade mRNA manufactured for use in vaccines, gene therapies, and nucleic acid therapeutics, produced in ISO-classified cleanroom suites.
• Co Cap™ A Proprietary mRNA co-transcriptional cap analog that enhances translational efficiency and protects against 5'–3' exonuclease degradation, available in research and GMP grades and custom formats.
• Biomanufacturing Services End-to-end GMP biomanufacturing services for nucleic acid products, delivered from ISO-classified cleanroom suites in Calgary, Alberta.
• Plasmid DNA Production Plasmid DNA production services from design through clinical or commercial scale, covering research, GLP, and GMP grades, with expertise in complex plasmid constructs.
• mRNA Production mRNA manufacturing services at RUO and GMP grades, supporting synthesis, purification, and formulation for therapeutic and vaccine developers.
• Microbial Cell Banking GMP microbial cell bank production services to support nucleic acid manufacturing programs.
• Chemical Manufacturing Chemical manufacturing of cap analogs and lipids at gram to kilogram scale, including custom and generic ionizable lipids for LNP formulations.
• R&D Development Services R&D services including vaccine construct design, sequence optimization, UTR optimization, and formulation development for nucleic acid products.
• LNP Formulation Single-use GMP-grade LNP particle-formation and downstream platform for nucleic acid delivery, with reproducible production from 100 mL to 10 L scales.
• Analytical and Stability Testing Analytical and stability testing services for nucleic acid products, including advanced impurity detection for cap analogs.
• Storage Services Cold chain storage and distribution services for nucleic acid products at chilled, frozen, and cryogenic conditions.

Quantifiable outcome

• Single-use GMP LNP platform achieves particle size 50-120 nm, PDI ≤ 0.2, and encapsulation efficiency ≥85%
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Genvax TechnologiescoreStrategic or Co-development Partner · 3 December 2025Northern RNA serves as Genvax's contract manufacturer for scalable production of proprietary lipid used to encapsulate their RNA-based swine influenza vaccine. Northern RNA's GMP-grade facilities and expertise support Genvax's commercialization efforts for their first saRNA-based animal vaccine expected to launch in 2027. This collaboration reflects shared commitment to leveraging RNA technologies for real-world applications.
• Kaster TechnologiesminorStrategic or Co-development Partner · 28 October 2024Memorandum of Understanding signed to explore digital tools for optimizing drug and life science manufacturing. Partnership aims to leverage Northern RNA's expertise in scalable nucleic acid manufacturing with Kaster Technologies' advanced digital tools to improve operational efficiency and reduce global drug shortages. Initial focus on applying Kaster's digital tools at Northern RNA's Lipids Manufacturing Facility.
• Galenvs SciencescoreStrategic or Co-development Partner · 1 October 2024Collaboration to advance the future of synthetic RNA manufacturing in Canada, expanding capabilities across therapeutic oligonucleotide space including siRNA, sgRNA, ASO, and PMO manufacturing technologies. Combined expertise drives innovation and sets new standards in RNA therapeutics. Foundation for breakthroughs in rare diseases, cancer, and complex health challenges.
• SyVento BioTechminorStrategic or Co-development Partner · 21 August 2024Extended collaboration focused on collaborative scientific and development projects in mRNA therapeutics. Leverages combined expertise to unlock new possibilities in mRNA therapeutics for more effective, safer, and better tolerated treatments. Includes regulatory expertise sharing and product delivery efficiency enhancements. Represents commitment to advancing next-generation mRNA therapies.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• GenScript ProBio: GenScript ProBio is a CDMO division of GenScript offering plasmid DNA, mRNA, viral vector, and cell therapy manufacturing. Its GMP nucleic acid services and process development expertise make it a relevant direct peer to Northern RNA, particularly for Asian and North American biotech customers.
• Aldevron: Aldevron is a leading nucleic acid CDMO specializing in plasmid DNA, mRNA, and protein manufacturing for therapeutic developers. Acquired by Danaher for $9.6 billion, it is the most direct comparable to Northern RNA given the overlapping plasmid DNA + mRNA manufacturing capabilities and customer base.
• TriLink BioTechnologies (Maravai LifeSciences): TriLink is a specialist mRNA and nucleic acid CDMO now part of Maravai LifeSciences. It manufactures GMP-grade mRNA, cap analogs (CleanCap), and lipid nanoparticles — the closest technology-overlap competitor to Northern RNA's Co Cap™ A and LNP platform.

Broad incumbents

• Lonza: Lonza is one of the world's largest CDMOs offering mammalian, microbial, and nucleic acid manufacturing services. Its mRNA and lipid nanoparticle capabilities for vaccines and therapeutics put it in direct competition with Northern RNA for biotech CDMO contracts at higher volume scales.
• Curia (formerly AMRI): Curia is a contract development and manufacturing organization offering small molecule and biologics services with nucleic acid production capabilities. Its scale and integrated drug substance + drug product offering make it a broader competitor for CDMO contracts in the nucleic acid space.
• Catalent: Catalent is a top-tier global CDMO with significant mRNA and LNP formulation capabilities, having manufactured COVID-19 vaccines at commercial scale. As a broad incumbent with much larger capacity, it competes for the same biotech customers as Northern RNA but at far greater scale.
• WuXi STA (WuXi AppTec): WuXi STA is one of Asia's largest CDMOs offering comprehensive nucleic acid and biologics manufacturing. While geographically distant, its scale, pricing, and nucleic acid platform breadth make it a competitor for global biotech customers evaluating CDMO partners including Northern RNA.
• Thermo Fisher Scientific (Patheon CDMO): Thermo Fisher's Pharma Services division (incorporating Patheon) provides end-to-end CDMO capabilities including nucleic acid production and fill/finish. As a global life sciences incumbent with significant balance sheet capacity, it competes with Northern RNA for high-value mRNA and LNP manufacturing contracts.

Emerging players

• eTheRNA immunotherapies: eTheRNA is a clinical-stage mRNA therapeutics developer with in-house manufacturing expertise and TriMix adjuvant platform. As a technology-adjacent player in the mRNA CDMO and therapeutics space, it represents an emerging competitor or potential partner for specialized mRNA manufacturing services.

Regional players

• Biovectra: Biovectra is a Canadian CDMO specializing in complex biologics, small molecule APIs, and nucleic acid manufacturing from Atlantic Canada. Its geographic proximity and overlapping nucleic acid capabilities make it a relevant regional peer for Northern RNA in the Canadian biotech ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInca.linkedin.com/company/northernrna

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Northern RNA